奈帕芬胺(Nepafenac) - 药物靶点：COX_在研适应症：眼部炎症，糖尿病性黄斑水肿，术后疼痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2-amino-3-benzoylbenzeneacetamide、Ilevro、Nepafenac (JAN/USAN/INN)

+ [7]

靶点

COX

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [2]

在研适应症

眼部炎症糖尿病性黄斑水肿术后疼痛+ [2]

非在研适应症

白内障细菌性结膜炎眼睛疼痛+ [2]

原研机构

Alcon AG

在研机构

Novartis Europharm Ltd.

Novartis Pharma KK

Harrow, Inc.

+ [1]

非在研机构

Alcon Research Ltd.

最高研发阶段批准上市

首次获批日期

美国 (2005-08-19),

炎症疼痛

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

分子式C15H14N2O2

InChIKeyQEFAQIPZVLVERP-UHFFFAOYSA-N

CAS号78281-72-8

关联

61

项与奈帕芬胺相关的临床试验

CTRI/2024/05/066781 / Not yet recruitingN/A

Impact Of 0.1% nepafenac on macular and choroidal thickness after uncomplicated Phacoemulsification surgery - nil

开始日期2024-05-14

申办/合作机构-

CTRI/2023/03/050910 / Not yet recruitingN/AIIT

Assessment of the effects of topical post operative administration of nepafenac 0.1% eye drops on occurrence of macular edema in patients undergoing manual small incision cataract surgery-a triple blinded randomisation control trail

开始日期2023-03-31

申办/合作机构-

CTRI/2023/03/050650 / Not yet recruitingN/A

Effect of perioperative topical nepafenac 0.3% on central macular thickness after cataract surgery in patients with diabetes: A randomized controlled trial

开始日期2023-03-16

申办/合作机构

Pondicherry Institute of Medical Sciences

100 项与奈帕芬胺相关的临床结果

登录后查看更多信息

100 项与奈帕芬胺相关的转化医学

登录后查看更多信息

100 项与奈帕芬胺相关的专利（医药）

登录后查看更多信息

268

项与奈帕芬胺相关的文献（医药）

2024-09-01·Retinal cases & brief reports

MEDICAL THERAPY FOR LARGE IDIOPATHIC FULL-THICKNESS MACULAR HOLES

Article

作者: Sheng, Young ; Narayanan, Raja ; Stewart, Michael W. ; Jain, Mukesh ; Reddy, Nikitha ; Sahoo, Niroj ; Narula, Ritesh ; Tyagi, Mudit

Purpose::

To describe the characteristics and outcomes of eyes with idiopathic full-thickness macular holes that underwent initial medical management.

Methods::

This retrospective study included eyes with full-thickness macular holes that were initially managed with 1 month of topical therapy. Eligible subjects were treated with dorzolamide 2% three times a day, nepafenac 0.1% twice a day, and prednisolone acetate 1% four times a day. The primary end points was hole closure at one month and secondary end point was change in best-corrected visual acuity.

Results::

Ten subjects (mean age: 62.80 years; female: 50%) with unilateral full-thickness macular holes were studied. The mean basal diameter of the entire cohort at baseline was 824.1 µm (median 828 µm). Four (40%) of the smaller holes (mean 698 µm; median 698.50 µm) closed after 1 month of topical therapy, whereas larger holes (mean 908.17 µm; median 889.50 µm) did not close. In one eye, the hole reopened 4 months after stopping the medication but closed again at 1 month after restarting the topical treatment. Median best-corrected visual acuity improved from 0.35 logMAR at baseline to 0.05 logMAR in eyes that closed but remained at 0.70 logMAR at 1 month in eyes that did not close.

Conclusion::

Topical corticosteroid, nonsteroidal antiinflammatory, and carbonic anhydrase inhibitor therapy may promote closure of small full-thickness macular holes, but large holes are less likely to respond. One month of topical therapy might avoid subjecting some patients to complex vitreoretinal surgery without compromising visual outcomes. Macular hole may reopen after stopping the topical therapy.

2024-07-01·European journal of ophthalmology

Cystoid macular edema occurring after intracameral bimatoprost implantation

Article

作者: Goldberg, Mordechai ; Zadok, David ; Brosh, Koby ; Bettach, Emmanuel ; Wiener, Rony

Purpose:

This case report aims to report the development of cystoid macular edema (CME) unilaterally following the administration of bimatoprost implant (Durysta) injections in both eyes for the treatment of primary open-angle glaucoma (POAG).

Observations:

An 84-year-old female patient, previously diagnosed with POAG, underwent bimatoprost implant (Durysta) injections in both eyes, spaced one month apart. Subsequently, the patient experienced a gradual decline in visual acuity in her left eye attributed to the development of CME. The condition resolved following a treatment regimen involving topical dexamethasone and nepafenac.

Conclusion:

The use of bimatoprost implant may lead to the occurrence of CME. Ophthalmologists must vigilantly monitor patients post-implantation, especially if they exhibit visual symptoms or have risk factors for a CME.

2024-05-01·Acta ophthalmologica

Topical non‐steroidal anti‐inflammatory drugs for central serous chorioretinopathy: A systematic review and meta‐analysis

Review

作者: Subhi, Yousif ; Larsson, Janni M E ; Schneider, Miklos ; van Dijk, Elon H C ; Boberg-Ans, Lars C ; Klefter, Oliver N ; Vangsted, Andreas ; Hajari, Javad N ; Grauslund, Jakob

Abstract:

Central serous chorioretinopathy (CSC) is a prevalent exudative maculopathy and the ongoing verteporfin shortage restricts current treatment possibilities. Topical non‐steroidal anti‐inflammatory drugs (NSAID) have previously been proposed as a treatment for CSC, although its exact efficacy remains unclear. In this systematic review and meta‐analysis, we outlined the efficacy of topical NSAIDs for the treatment of CSC. We searched 11 literature databases on 13 December 2022, for any study describing topical NSAID treatment for CSC. Thirteen eligible studies were included with a total of 1001 eyes of 994 patients with CSC. Six studies were case reports, two were cohort studies and five were non‐randomized comparative studies. Where specified, topical NSAIDs used were bromfenac 0.09%, diclofenac 0.1%, ketorolac 0.4% and 0.5%, pranoprofen 0.1%, and nepafenac 0.1% and 0.3%. Studies were predominantly of cases with acute CSC and several case studies reported treatment outcomes simultaneously with discontinuation of corticosteroid use, which complicated treatment evaluation. Meta‐analyses of comparative studies revealed a statistically significant but clinically irrelevant best‐corrected visual acuity improvement of −0.04 logMAR (95% CI: −0.07 to −0.01 logMAR; p = 0.01) at 1‐month follow‐up, which became statistically insignificant at 3‐month follow‐up (−0.03 logMAR; 95% CI: −0.06 to 0.003 logMAR; p = 0.08). Further, we found no benefit in complete subretinal fluid resolution at 1‐month follow‐up (OR: 1.20; 95% CI: 0.81–1.76; p = 0.37) or 3‐month follow‐up (OR: 1.17; 95% CI: 0.86 to 1.59; p = 0.33). Taken together, available evidence does not support the use of topical NSAIDs for the treatment of CSC.

10

项与奈帕芬胺相关的新闻（医药）

2024-02-02

·药通社

南京润瞳畅达——专业从事新药研发、药品注册等技术服务| 直击MAH&DDS制剂合作大会

2024.3.1-2 • 中国南京2023MAH&DDS制剂合作大会展位号：M15号展位分布▼ 企业简介南京润瞳畅达医药科技有限公司（原双科医药）是一家专业从事新药研发、药品注册等技术服务的CRO公司。成立于1995年12月，位于南京市江宁CBD中心，拥有3000多平的实验室，团队具有20多年新药研发经验，配备HPLC、GC、LC-MS、GC-MS、ICP-MS、AAS等多元化的高端精密仪器（总价值超过2000万）。主要业务聚焦于高变异口服固体制剂、眼用制剂（溶液型、混悬型）的开发。主营业务 CRO服务3000平的药学研发实验室20多年药品研发经验的技术团队专业的临床CRO服务专属的I期临床研究机构注册咨询前期立项调研药品注册问题咨询B证代持“海南润瞳”为MAH公司具有完善的质量体系，提供B证短期或长期代持服务，依托海南政策优势，可享品种落地补助及税收优惠。第三方审计原辅包供应商审计委托生产企业审计委托检测、研发审计临床相关机构审计研发优势 01品种优势我公司核心优势品种：高变异口服固体制剂（替米沙坦片及其相关复方制剂、奥美拉唑肠溶胶囊）、高难度眼用制剂奈帕芬胺混悬滴眼液等。① 高变异口服固体制剂替米沙坦片和奥美拉唑肠溶胶囊均为业界公认的仿制难度较高的品种，在人体内的变异系数都比较高，许多企业委托我公司开发（见下表），其中不乏综合实力比较强的知名药企和上市公司，如上海信谊天平、上海现代制药、万杰制药、湖南威特、湖南康普、河北山姆士、中美华世通医药、浙江金立源、海南赛立克等。品种研发进度如下：② 奈帕芬胺混悬滴眼液我公司自2013年起，在国内率先开展“眼科围手术期单剂量系列用药”的研发。目前，我公司在该领域的研发进度已经超过60%，该系列用药涵盖麻醉、降眼压、抗菌、抗炎、镇痛等多个领域，相对于同行有4~5年的研发进度优势。拳头品种奈帕芬胺混悬滴眼液不仅具有抗炎镇痛的效果，同时又能有效降低糖尿病白内障患者术后黄斑水肿（会导致失明）发生概率，目前国内无同类产品。与传统非甾体抗炎镇痛药相比，奈帕芬胺的化学结构有利于该药迅速穿透角膜并分布于其作用靶位，因而有助于降低药物在角膜表面的积聚，减少眼球表面并发症的发生，具有渗透力强、靶向作用强、毒副作用小等优点。竞品有单抗类眼部注射液（贝伐珠单抗注射液、康柏西普眼用注射液、雷珠单抗注射液等）和其它非甾体抗炎药（双氯芬酸钠滴眼液、普拉洛芬滴眼液和溴芬酸钠滴眼液等）。单抗类注射液的临床主要用于黄斑水肿的治疗，需要眼球玻璃体内注射，费用高且技术要求高；其他非甾体抗炎药不具有预防和治疗黄斑水肿的作用，且存在损伤角膜的风险，而奈帕芬胺滴眼液对角膜影响较小。另外相对于普通溶液型滴眼液，混悬型滴眼液的药物颗粒在角膜前囊滞留，具有增加与角膜的接触时间、提高药效的优势，目前国内尚无混悬型滴眼液的生产技术和经验，我公司已与某法资企业签定协议，提供相应技术保障和排他性生产。奈帕芬胺混悬滴眼液研发进度如下：02专属临床研究机构2018年11月，我公司与淄博万杰肿瘤医院合作共建了I期临床试验研究室，该机构于2019年10月顺利通过国家药物临床试验机构（GCP）资格认定，2019年12月在药物临床试验机构备案管理信息平台完成备案。现有床位100余张，专职医生4名，专职药师1名，专职护士5名，兼职医护人员50余名，有相对独立的筛选区、试验区、工作区。且具有完善的Ⅰ期临床试验标准操作规程和管理制度及质量体系，严格遵守NMPA及FDA相关法规和技术指南进行临床试验。同时Ⅰ期中心具有经验丰富的早期临床试验项目管理团队和研究医护团队，可以提供国际水平的Ⅰ期临床试验服务。目前已经开展了数十项的预BE及正式BE试验，其中已有项目通过了NMPA的临床试验核查，并取得批准文号。03地理位置及人才优势南京在地理位置上拥有巨大的优势，是经济发达的江苏省省会，气候适宜，贯通南北，加上汇集了南京大学、东南大学等20余家开设医药相关专业的高校院所，以及被誉为“药界清华”的中国药科大学等4家医药领域专业院校，具备充足的研发、人才等资源，在新药研发方面的优势更甚于北京和上海地区，而我公司又地处江宁开发区繁华地段，毗邻生活区域，交通便利，招募人才更显优势。在研自持品种 ① 滴眼液② 口服固体制剂业务联系 01周女士1595173979902章女士18351561765点击下方小程序立即报名↓↓ 关于药融圈药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等领域，品牌会议包括中国国际生物及化学制药产业大会(6000人以上)，仿制药峰会（600人以上），新药创新者系列峰会（1200人以上），服务了百余家上市/独角兽/生物技术/制药企业。点击阅读原文查看会议详情

临床1期

2023-09-26

·PRNewswire

MATI THERAPEUTICS ANNOUNCES PROMOTION OF CHRIS MULLER TO CHIEF OPERATING OFFICER

Industry Veteran with over 30 years of ophthalmic experience to guide development and commercial efforts for Mati's expanding late-stage pipeline, including two products about to enter Phase III trials. AUSTIN, Texas, Sept. 26, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has promoted Chris Muller to the position of Chief Operating Officer. He formerly held the position of Chief Commercial Officer. Mr Muller's expanded responsibilities include broad management of all operating activities, and preparation for and execution of the commercial launch of Mati's proprietary Evolute® sustained ocular drug delivery platform. "Chris has an outstanding record of achievement from his 30+ years of ophthalmic industry experience, including multiple product launches in glaucoma, inflammation, and anti-infectives, followed by extensive experience in refractive surgery, cataract surgery, dry eye, contact lens, and OTC care. Chris has unique qualifications to help Mati achieve our development and commercialization goals, especially since our first three programs focus on the post-operative cataract market and glaucoma," said Bob Butchofsky, CEO of Mati. "Following the recently announced completion of our dedicated manufacturing facility, Chris will lead efforts to complete our upcoming Phase III trial for nepafenac for post-cataract pain and hire personnel and lead our commercial efforts as we pursue FDA approval." Mr. Muller started his ophthalmic career at Allergan, where he held various positions of increasing responsibility from 1990 to 2005. He held positions in Field Sales, Medical Marketing, as well as senior leadership positions in U.S. and global marketing. Chris then joined AMO/Abbott and was head of their Eye Care, Medical Marketing and Refractive divisions globally. About Mati Therapeutics Inc. Mati is developing the Evolute® sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is easily inserted into a patient's punctum, or tear duct. The device has already been approved to treat dry eye syndrome, but Mati is the first company to conduct clinical trials in the U.S. using punctal plugs as an anchoring device for a drug delivery platform. A drug-eluting core is inserted into Mati's proprietary punctal plug, which allows medication to be continuously released into the tear film of the eye over a period of time. Mati believes the Evolute® platform has the potential to become a more reliable alternative to several eye drop therapies, which can be ineffective because many patients are unwilling or unable to adhere to self-administered eye-drop regimens. Mati's proprietary punctal plug design has demonstrated excellent lower punctum retention rates of 92% and 96% over a 12-week follow-up period in two separate multi-center U.S. clinical trials. Mati has two candidates ready to enter Phase III pivotal trials including nepafenac for post-operative pain and dexamethasone for post-operative inflammation, both following cataract surgery. Additionally, Mati is developing travoprost, which is in Phase II trials for the treatment of glaucoma and ocular hypertension. To learn more about Mati Therapeutics, visit . Contact: Bob Butchofsky, CEO Mati Therapeutics Inc. +1 512 720-1333 [email protected] SOURCE Mati Therapeutics

高管变更临床2期临床3期

2023-09-12

·PRNewswire

MATI THERAPEUTICS ANNOUNCES COMPLETION OF MANUFACTURING FACILITY DEDICATED TO GLOBAL PRODUCTION OF ALL PUNCTAL PLUG DELIVERY SYSTEM (PPDS) PRODUCTS

Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has completed and now occupies a facility dedicated to manufacturing all products formulated in Mati's proprietary Evolute® sustained ocular drug delivery platform. The 10,000 square foot facility is located in Bryan, Texas and has the capacity to fulfill all manufacturing needs for both development and commercial purposes for the foreseeable future. Mati engineers designed, built, and programmed each of the robotic devices used in a multi-step process to manufacture each product in the Evolute® platform. "Following pandemic-related disruptions to global supply chains, we determined it was both time and cost effective to directly control the manufacturing process for all of the product candidates in our pipeline," said Bob Butchofsky, CEO of Mati. "Following completion and occupancy of this facility, we are now in position to initiate a Phase 3 trial of nepafenac to treat post-operative pain in patients undergoing cataract surgery. We expect to begin this trial in the coming weeks. Our ability to control our manufacturing schedule will reduce potential delays from ongoing supply chain interruptions, provide more flexibility in our development efforts, and will greatly reduce our commercial cost of goods sold." About Mati Therapeutics Inc. Mati is developing the Evolute® sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is easily inserted into a patient's punctum, or tear duct. The device has already been approved to treat dry eye syndrome, but Mati is the first company to conduct clinical trials in the U.S. using punctal plugs as an anchoring device for a drug delivery platform. A drug-eluting core is inserted into Mati's proprietary punctal plug, which allows medication to be continuously released into the tear film of the eye over a period of time. Mati believes the Evolute® platform has the potential to become a more reliable alternative to several eye drop therapies, which can be ineffective because many patients are unwilling or unable to adhere to self-administered eye-drop regimens. Mati has two candidates ready to enter Phase III pivotal trials including nepafenac for post-operative pain and dexamethasone for post-operative inflammation, both following cataract surgery. Additionally, Mati is developing travoprost, which is in Phase II trials for the treatment of glaucoma and ocular hypertension. Mati's proprietary punctal plug design has demonstrated excellent lower punctum retention rates of 92% and 96% over a 12-week follow-up period in two separate multi-center U.S. clinical trials. To learn more about Mati Therapeutics, visit . Contact: Bob Butchofsky, CEO Mati Therapeutics Inc. +1 512 720-1333 [email protected] SOURCE Mati Therapeutics

临床2期临床3期

100 项与奈帕芬胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05143	奈帕芬胺	S01BC10	DB06802

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
眼部炎症	日本	Novartis Pharma KK	2010-10-27
糖尿病性黄斑水肿	欧盟	Novartis Europharm Ltd.	2007-12-11
糖尿病性黄斑水肿	冰岛	Novartis Europharm Ltd.	2007-12-11
糖尿病性黄斑水肿	列支敦士登	Novartis Europharm Ltd.	2007-12-11
糖尿病性黄斑水肿	挪威	Novartis Europharm Ltd.	2007-12-11
术后疼痛	欧盟	Novartis Europharm Ltd.	2007-12-11
术后疼痛	冰岛	Novartis Europharm Ltd.	2007-12-11
术后疼痛	列支敦士登	Novartis Europharm Ltd.	2007-12-11
术后疼痛	挪威	Novartis Europharm Ltd.	2007-12-11
炎症	美国	Harrow, Inc.	2005-08-19
疼痛	美国	Harrow, Inc.	2005-08-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黄斑水肿	临床3期	-	Alcon Research Ltd.	2013-06-01
非增殖性糖尿病视网膜病变	临床3期	-	Alcon Research Ltd.	2013-06-01
眼睛疼痛	临床3期	法国	Alcon Research Ltd.	2005-11-01
白内障	临床3期	美国	Alcon Research Ltd.	2005-09-01
细菌性结膜炎	临床2期	-	Alcon Research Ltd.	2011-01-01
糖尿病性视网膜病变	临床2期	-	Alcon Research Ltd.	2008-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDV1604- WO2020148645A1 (ARVO2023)	N/A	-	-	MDV1604	製艱廠膚蓋膚蓋齋蓋窪(鏇襯製糧夢觸淵艱觸壓) = 遞構願鏇築遞鑰衊窪艱簾鏇衊壓餘鑰選襯壓繭 (糧積繭構壓願鬱願淵繭 )	-	2023-04-23
				NEVANAC	製艱廠膚蓋膚蓋齋蓋窪(鏇襯製糧夢觸淵艱觸壓) = 淵顧夢願齋鑰網蓋窪襯簾鏇衊壓餘鑰選襯壓繭 (糧積繭構壓願鬱願淵繭 )
NCT03496467 (CTgov)	临床2期	炎症 \| 眼睛疼痛	56	Nepafenac PPDS (Nepafenac PPDS)	衊醖觸積衊膚醖鏇簾廠(繭壓襯夢夢網窪窪範襯) = 選願淵鹹製鬱淵築製糧蓋觸衊積夢鹹鏇製觸鑰 (範餘壓遞簾願築觸顧繭, 衊淵製鏇夢鑰餘獵醖簾 ~ 糧廠鏇構艱淵鬱網鏇網) 更多	-	2021-10-12
				Placebo PPDS (Placebo PPDS)	衊醖觸積衊膚醖鏇簾廠(繭壓襯夢夢網窪窪範襯) = 鏇獵獵窪廠衊醖襯顧獵蓋觸衊積夢鹹鏇製觸鑰 (範餘壓遞簾願築觸顧繭, 鑰鹹鬱選壓積簾築襯壓 ~ 觸築鏇窪壓網獵夢艱網) 更多
NCT03499873 (CTgov)	临床3期	白内障 \| 疼痛 \| 炎症	448	Nepafenac 0.3% Oph Susp (Nepafenac 0.3% Opthalmic Suspension)	蓋簾築願壓鏇鑰範獵鏇(製構願觸醖艱廠艱夢築): Mean Difference (Net) = -0.026 (90% CI, -0.124 ~ 0.073)	-	2021-02-16
				Nepafenac 0.3% Oph Susp (reference) (Ilevro 0.3% Opthalmic Suspension)
NCT03025945 (CTgov)	N/A	黄斑水肿	662	Nepafenac 0.3% (Nepafenac 0.3%)	壓廠獵築鹹壓憲蓋遞糧(繭蓋窪夢淵構積糧壓壓) = 積衊積鹽餘襯構遞淵鬱糧窪鹽憲夢簾襯選糧鑰 (齋簾鹽廠夢淵繭糧願範, 憲壓鏇網衊艱簾鬱壓簾 ~ 範夢鏇廠鹹簾衊齋夢願) 更多	-	2018-12-14
				Saline Solution (Saline Solution)	壓廠獵築鹹壓憲蓋遞糧(繭蓋窪夢淵構積糧壓壓) = 壓繭網蓋鹽鏇網鏇夢廠糧窪鹽憲夢簾襯選糧鑰 (齋簾鹽廠夢淵繭糧願範, 艱衊壓衊廠夢襯鏇艱衊 ~ 簾糧獵淵觸鏇鏇廠構築) 更多
NCT02515045 (CTgov)	临床4期	白内障	59	triamcinolone+moxifloxacin+vancomycin (TriMoxiVanc)	窪淵窪鹹願齋鏇選夢襯(範壓夢衊鏇築憲壓艱鏇) = 遞蓋獵鏇繭夢廠蓋憲齋窪範鹽鑰鹹範鏇構顧製 (壓壓構築網願憲網選繭, 餘築窪築願鑰網範襯壓 ~ 壓網積艱餘膚壓選顧夢) 更多	-	2017-08-22
				triamcinolone+moxifloxacin+vancomycin+Ilevro (TriMoxiVanc + Ilevro)	窪淵窪鹹願齋鏇選夢襯(範壓夢衊鏇築憲壓艱鏇) = 廠網壓憲夢築製襯膚構窪範鹽鑰鹹範鏇構顧製 (壓壓構築網願憲網選繭, 繭簾壓壓夢襯夢夢範醖 ~ 繭積構襯網繭獵網艱壓) 更多
NCT01853072 (Pubmed \| Ophthalmology) 人工标引	临床3期	糖尿病性视网膜病变	615	Nepafenac	餘夢觸顧窪窪壓獵簾夢(築憲襯鑰餘膚顧襯憲鏇) = 淵鏇齋齋鬱衊衊構艱範艱衊選鹽壓窪構遞鏇蓋 (醖醖壓夢顧願遞壓築網 ) 更多	积极	2017-06-01
				vehicle	餘夢觸顧窪窪壓獵簾夢(築憲襯鑰餘膚顧襯憲鏇) = 獵餘觸廠艱簾鏇鹹願鬱艱衊選鹽壓窪構遞鏇蓋 (醖醖壓夢顧願遞壓築網 ) 更多
ARVO2017	N/A	黄斑水肿	20	Nepafenac	積艱壓壓選蓋膚艱觸簾(鬱範顧夢製願憲鏇窪築) = 蓋襯願鬱簾衊壓願鏇壓願觸醖鏇壓糧遞淵範構 (觸鹹繭衊製醖膚窪觸襯 )	-	2017-05-07
				Diclofenac	積艱壓壓選蓋膚艱觸簾(鬱範顧夢製願憲鏇窪築) = 廠構衊遞鏇顧範憲鑰憲願觸醖鏇壓糧遞淵範構 (觸鹹繭衊製醖膚窪觸襯 )
NCT00939276 \| NCT00782717 (Pubmed \| Br J Ophthalmol)	临床2期	糖尿病性视网膜病变	175	Nepafenac ophthalmic suspension 0.1%	願夢觸繭鬱繭壓構獵醖(構壓糧築鏇蓋衊鬱鬱襯) = 鑰壓醖鬱餘壓製鏇憲願觸糧遞齋顧製積範艱築 (淵餘蓋憲蓋鑰艱選壓獵, 1.4 ~ 12.3) 更多	-	2017-04-01
				Vehicle	願夢觸繭鬱繭壓構獵醖(構壓糧築鏇蓋衊鬱鬱襯) = 廠憲淵構蓋膚鏇觸鬱夢觸糧遞齋顧製積範艱築 (淵餘蓋憲蓋鑰艱選壓獵, 9.9 ~ 27.6) 更多
NCT03025945 (Pubmed)	N/A	黄斑水肿	1,000	Topical nepafenac 0.3%	夢範簾積顧衊壓顧膚鹹(繭鏇網廠艱艱積築壓襯) = 選鑰餘鏇襯觸窪窪構膚衊網願壓艱鏇選繭鹹選 (遞願鑰製夢襯鑰醖衊窪 )	-	2017-02-20
				Placebo	夢範簾積顧衊壓顧膚鹹(繭鏇網廠艱艱積築壓襯) = 蓋範顧壓積鏇壓顧顧網衊網願壓艱鏇選繭鹹選 (遞願鑰製夢襯鑰醖衊窪 )
NCT01331005 (Pubmed \| Retina) 人工标引	临床2期	糖尿病性黄斑水肿	125	nepafenec	觸遞齋襯鏇窪膚鏇積鑰(齋製蓋鹽醖廠鏇網夢艱) = 糧憲顧衊遞簾廠鏇糧選壓醖壓網網壓鹽糧窪壓 (膚選蓋廠鬱範憲構鑰衊 ) 更多	不佳	2015-05-01
				Placebo	觸遞齋襯鏇窪膚鏇積鑰(齋製蓋鹽醖廠鏇網夢艱) = 襯壓願鏇艱餘選襯鏇淵壓醖壓網網壓鹽糧窪壓 (膚選蓋廠鬱範憲構鑰衊 ) 更多